Afucoâ„¢ Anti-Human AOC3 ADCC Theraputic Antibody (BTT-1023), ADCC Enhanced

Anti-AOC3 ADCC Enhanced Antibody (BTT-1023) is an ADCC enhanced antibody produced by our Afucoâ„¢ platform. BTT1023 is a fully human monoclonal antibody targeting VAP-1 (vascular adhesion protein-1). VAP-1 is a completely new therapeutic target. The safety and efficacy of BTT1023 has earlier been investigated in small clinical trials in rheumatoid arthritis and psoriasis patients. In March 2015, BTT1023 transitioned into Phase 2 development in fibrotic conditions and received Orphan Drug Designation in the EU for the treatment of primary sclerosing cholangitis.
https://www.creativebiolabs.net/Anti-AOC3-ADCC-Enhanced-Antibody-BTT-1023-20349.htm